TMCnet News

Roxadustat (FibroGen/Astellas/AstraZeneca) Drug Analysis 2018 - ResearchAndMarkets.com
[February 20, 2018]

Roxadustat (FibroGen/Astellas/AstraZeneca) Drug Analysis 2018 - ResearchAndMarkets.com


The "Drug Analysis: Roxadustat" drug pipelines has been added to ResearchAndMarkets.com's offering.

Roxadustat (FibroGen/Astellas/AstraZeneca) is a hypoxia-inducible factor (HIF) prolyl-hydroxylase inhibitor in development for the treatment of anemia in chronic kidney disease. The drug is administered orally three times per week and mimics the body's natural response to reduced oxygen levels by increasing levels of HIFs. These factors are involved in erythropoiesis. Roxadustat treats anemia primarily by reducing hepcidin levels, increasing iron transport and absorption proteins, and stimulating erythropoietin production.

Ke Topics Covered:



List of Figures

Figure 1: Roxadustat for anemia in chronic kidney disease - SWOT analysis


Figure 2: Drug assessment summary of roxadustat for anemia in chronic kidney disease

Figure 3: Drug assessment summary of roxadustat for anemia in chronic kidney disease

Figure 4: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015-24

List of Tables

Table 1: Roxadustat drug profile

Table 2: Roxadustat Phase III trials in anemia in chronic kidney disease

Table 3: Roxadustat Phase II and III data in anemia in chronic kidney disease

Table 4: Roxadustat sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015-24

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/t3xcgb/roxadustat?w=4


[ Back To TMCnet.com's Homepage ]